Our top pick for
Building a portfolio
Atea Pharmaceuticals, Inc is a biotechnology business based in the US. Atea Pharmaceuticals shares (AVIR) are listed on the NASDAQ and all prices are listed in US Dollars. Atea Pharmaceuticals employs 39 staff and has a trailing 12-month revenue of around USD$48.6 million.
|52-week range||USD$24.15 - USD$90.95|
|50-day moving average||USD$65.9877|
|200-day moving average||USD$53.2664|
|Wall St. target price||USD$82|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Atea Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atea Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Atea Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$12 million.
The EBITDA is a measure of a Atea Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
To put Atea Pharmaceuticals's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||USD$48.6 million|
|Operating margin TTM||24.7%|
|Gross profit TTM||USD$33.7 million|
|Return on assets TTM||1.7%|
|Return on equity TTM||-3.86%|
|Market capitalisation||USD$4.5 billion|
TTM: trailing 12 months
There are currently 3.1 million Atea Pharmaceuticals shares held short by investors – that's known as Atea Pharmaceuticals's "short interest". This figure is 38.5% up from 2.2 million last month.
There are a few different ways that this level of interest in shorting Atea Pharmaceuticals shares can be evaluated.
Atea Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Atea Pharmaceuticals shares currently shorted divided by the average quantity of Atea Pharmaceuticals shares traded daily (recently around 381409.57055215). Atea Pharmaceuticals's SIR currently stands at 8.15. In other words for every 100,000 Atea Pharmaceuticals shares traded daily on the market, roughly 8150 shares are currently held short.
To gain some more context, you can compare Atea Pharmaceuticals's short interest ratio against those of similar companies.
However Atea Pharmaceuticals's short interest can also be evaluated against the total number of Atea Pharmaceuticals shares, or, against the total number of tradable Atea Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atea Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Atea Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0414% of the tradable shares (for every 100,000 tradable Atea Pharmaceuticals shares, roughly 41 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Atea Pharmaceuticals.
Find out more about how you can short Atea Pharmaceuticals stock.
We're not expecting Atea Pharmaceuticals to pay a dividend over the next 12 months.
You may also wish to consider:
Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.